Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
Achieve Life Sciences presented positive 52-week results from the open-label ORCA-OL trial of cytisinicline at CHEST 2026, with four-week sustained abstinence rising from 25.5% at Weeks 9-12 to 31.2% during Weeks 49-52 in a hard-to-treat population. Among participants new to cytisinicline (prior placebo attempt), 39.4% had quit by Weeks 49-52; 69.7% of 479 enrolled completed the study with no new safety signals per the DSMC.
Key figures
- Drug Name
- cytisinicline
- Phase Of Trial
- Open-label long-term extension following Phase 3
- Enrolled
- 479
- Trial name
- ORCA-OL
- Completion rate
- 69.7%
- Median exposure days
- 361
- Week 9 12 abstinence
- 25.5%
- Week 49 52 abstinence
- 31.2%
- Prior placebo week 49 52 quit rate
- 39.4%
- Discontinuation treatment related ae
- 3.6%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.